Syneron Medical Ltd (ELOS) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Shares jump on tech boost; fragile yen on intervention watch
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla, AT&T, Biogen and Hasbro rise premarket; Uber, Enphase fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Syneron Medical Reports Third Quarter 2016 Revenue of $71.5 Million
November 9, 2016 7:01 AM ESTIRVINE, Calif., Nov. 9, 2016 /PRNewswire/ --Â Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, today announced financial results for the three month period ended September 30, 2016.
Third Quarter 2016 Financial Highlights:
Revenue of $71.5 million, up 15.3% year-over-year Product revenue up 18.6% year-over-year, including 19.5% North America and 18.1% international growth Emerging products revenue of $24.1 million, which represents the Company's strategic growth drivers, grew 61% year-over-year Total Body Shaping revenue of $14.2 million grew 46% year-over-year GAAP earnings per share of $0.02, compared to GAAP loss per... More
